Advertisement

CAN RISK STRATIFICATION TOOLS BE UTILIZED TO SAFELY DISCHARGE LOW-RISK FEBRILE NEUTROPENIC PATIENTS FROM THE EMERGENCY DEPARTMENT?

      Abstract

      Background

      Chemotherapy-induced febrile neutropenia (FN) is one of the more common oncological emergencies. Despite evidence in the oncology literature suggesting that low-risk cases of FN can be managed safely at home, most patients with FN who present to the emergency department (ED) are admitted. FN risk stratification methods, such as Multinational Association for Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores, may be useful when considering patient disposition. We sought to address whether the existing body of literature is adequate to support the use of these methods when treating patients with FN in the ED.

      Methods

      A PubMed search from January 1, 2016 to March 19, 2021 was performed using the following search strategy: “febrile neutropenia” OR (fever AND neutropenia)) AND (emerg* OR outpatient) AND (admit OR admission OR hospitalization). General review articles and case reports were omitted. Each of the articles selected underwent a structured review.

      Results

      The search yielded 371 articles, which were independently screened for relevance by two authors, and 23 articles were selected for inclusion. MASCC score was used in 10 of the identified studies and each of these studies concluded that the score was useful in the ED. Most of the identified studies found that CISNE score had a higher sensitivity than MASCC score (96.7% vs. 32.9%, respectively), but a lower specificity (22.2% vs. 89.5%).

      Conclusions

      FN risk stratifications tools, such as MASCC and CISNE scores, are supported by the existing literature and may be included as part of the decision-making process when considering patient disposition.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Freifeld AG
        • Bow EJ
        • Sepkowitz KA
        • et al.
        Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America.
        Clin Infect Dis. 2011; 52: e56-e93https://doi.org/10.1093/cid/cir073
        • Caggiano V
        • Weiss RV
        • Rickert TS
        Linde-Zwirble WT. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy.
        Cancer. 2005; 103: 1916-1924
        • Baugh CW
        • Faridi MK
        • Mueller EL
        • Camargo Jr, CA
        • Pallin DJ.
        Near-universal hospitalization of US emergency department patients with cancer and febrile neutropenia.
        PLoS One. 2019; 14e0216835https://doi.org/10.1371/journal.pone.0216835
        • Mueller EL
        • Jacob SA
        • Cochrane AR
        • Carroll AE
        • Bennett Jr., WE
        Variation in hospital admission from the emergency department for children with cancer: a Pediatric Health Information System study.
        Pediatr Blood Cancer. 2020; 67: e28140
        • Bavle A
        • Grimes A
        • Zhao S
        • et al.
        Cost-effectiveness and improved parent and provider satisfaction with outpatient management of pediatric oncology patients, with low-risk fever and neutropenia.
        J Pediatr Hematol Oncol. 2018; 40: e415-e420
        • Klastersky J
        • Paesmans M
        • Rubenstein EB
        • et al.
        The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients.
        J Clin Oncol. 2000; 18: 3038-3051
        • Bhardwaj PV
        • Emmich M
        • Knee A
        • et al.
        Use of MASCC score in the inpatient management of febrile neutropenia: a single-center retrospective study.
        Support Care Cancer. 2020; 29: 5905-5914
        • Carmona-Bayonas A
        • Gómez J
        • González-Billalabeitia E
        • et al.
        Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients.
        Br J Cancer. 2011; 105: 612-617
        • Zheng B
        • Toarta C
        • Cheng W
        • Taljaard M
        • Reaume N
        • Perry JJ.
        Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: a systematic review and meta-analysis.
        Crit Rev Oncol Hematol. 2020; 149102922
        • Haeusler GM
        • Thursky KA
        • Slavin MA
        • et al.
        Risk stratification in children with cancer and febrile neutropenia: a national, prospective, multicentre validation of nine clinical decision rules.
        EClinicalMedicine. 2020; 18100220https://doi.org/10.1016/j.eclinm.2019.11.013
        • García de Guadiana-Romualdo L
        • Jiménez-Santos E
        • Cerezuela-Fuentes P
        • et al.
        Analyzing the capability of PSP, PCT and sCD25 to support the diagnosis of infection in cancer patients with febrile neutropenia.
        Clin Chem Lab Med. 2019; 57: 540-548
        • García de Guadiana-Romualdo L
        • Cerezuela-Fuentes P
        • Español-Morales I
        • et al.
        Prognostic value of procalcitonin and lipopolysaccharide binding protein in cancer patients with chemotherapy-associated febrile neutropenia presenting to an emergency department.
        Biochem Med (Zagreb). 2019; 29010702
        • Kelly RS
        • Lasky-Su J
        • Yeung SJ
        • et al.
        Integrative omics to detect bacteremia in patients with febrile neutropenia.
        PLoS One. 2018; 13e0197049https://doi.org/10.1371/journal.pone.0197049
        • Mohindra R
        • Mathew R
        • Yadav S
        • Aggarwal P.
        CISNE versus MASCC: identifying low risk febrile neutropenic patients.
        Am J Emerg Med. 2020; 38: 2259-2263
        • Haeusler GM
        • Gaynor L
        • Teh B
        • et al.
        Home-based care of low-risk febrile neutropenia in children-an implementation study in a tertiary paediatric hospital.
        Support Care Cancer. 2021; 29: 1609-1617
        • Gunderson CC
        • Erickson BK
        • Wilkinson-Ryan I
        • et al.
        Prospective evaluation of multinational association of supportive care in cancer risk index score for gynecologic oncology patients with febrile neutropenia.
        Am J Clin Oncol. 2019; 42: 138-142
        • Ying FLM
        • Ping MCY
        • Tong M
        • et al.
        A cohort study on protocol-based nurse-led out-patient management of post-chemotherapy low-risk febrile neutropenia.
        Support Care Cancer. 2018; 26: 3039-3045
        • Ahn S
        • Rice TW
        • Yeung SJ
        • Cooksley T.
        Comparison of the MASCC and CISNE scores for identifying low-risk neutropenic fever patients: analysis of data from three emergency departments of cancer centers in three continents.
        Support Care Cancer. 2018; 26: 1465-1470
        • Coyne CJ
        • Le V
        • Brennan JJ
        • et al.
        Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department.
        Ann Emerg Med. 2017; 69: 755-764
        • Ding S
        • Ma J
        • Song X
        • et al.
        Diagnostic accuracy of procalcitonin, neutrophil-to-lymphocyte ratio, and C-reactive protein in detection of bacterial infections and prediction of outcome in nonneutropenic febrile patients with lung malignancy.
        J Oncol. 2020; 20202192378https://doi.org/10.1155/2020/2192378
        • Haeusler GM
        • Thursky KA
        • Mechinaud F
        • et al.
        Predicting infectious complications in children with cancer: an external validation study.
        Br J Cancer. 2017; 117: 171-178
        • Jansma B
        • Vakkalanka P
        • Talan DA
        • Negaard B
        • Faine BA.
        Guideline adherence for the management of emergency department patients with febrile neutropenia and no infection source: is there room for improvement?.
        J Oncol Pharm Pract. 2020; 26: 1382-1389
        • Kim M
        • Ahn S
        • Kim WY
        • et al.
        Predictive performance of the quick Sequential Organ Failure Assessment score as a screening tool for sepsis, mortality, and intensive care unit admission in patients with febrile neutropenia.
        Support Care Cancer. 2017; 25: 1557-1562
        • Marshall W
        • Campbell G
        • Knight T
        • Al-Sayed T
        • Cooksley T.
        Emergency ambulatory management of low-risk febrile neutropenia: multinational association for supportive care in cancer fits-real-world experience from a UK cancer center.
        J Emerg Med. 2020; 58: 444-448
        • Paolino J
        • Mariani J
        • Lucas A
        • et al.
        Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia.
        Pediatr Blood Cancer. 2019; 66: e27679
        • Baugh CW
        • Wang TJ
        • Caterino JM
        • et al.
        Emergency department management of patients with febrile neutropenia: guideline concordant or overly aggressive?.
        Acad Emerg Med. 2017; 24: 83-91
        • Cooksley T
        • Campbell G
        • Al-Sayed T
        • LaMola L
        • Berman R.
        A novel approach to improving ambulatory outpatient management of low risk febrile neutropenia: an Enhanced Supportive Care (ESC) clinic.
        Support Care Cancer. 2018; 26: 2937-2940
        • Nguyen M
        • Jacobson T
        • Torres J
        • Wann A.
        Potential reduction of hospital stay length with outpatient management of low-risk febrile neutropenia in a regional cancer center.
        Cancer Rep (Hoboken). 2021; 4: e1345
        • Moon H
        • Choi YJ
        • Sim SH.
        Validation of the Clinical Index of Stable Febrile Neutropenia (CISNE) model in febrile neutropenia patients visiting the emergency department. Can it guide emergency physicians to a reasonable decision on outpatient vs. inpatient treatment?.
        PLoS One. 2018; 13e0210019
        • Taj M
        • Nadeem M
        • Maqsood S
        • Shah T
        • Farzana T
        • Shamsi TS.
        Validation of MASCC score for risk stratification in patients of hematological disorders with febrile neutropenia.
        Indian J Hematol Blood Transfus. 2017; 33: 355-360
        • Janssens KP
        • Valete COS
        • Silva ARAD
        • Ferman SE.
        Evaluation of risk stratification strategies in pediatric patients with febrile neutropenia.
        J Pediatr (Rio J). 2021; 97: 302-308